Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | ACACA | Q13085 | 2/20 | 0.32 |
| ▸ | CTSS | P25774 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL147566 | 0.84 | ACACA (0.34) | ACACA | |
| SCHEMBL9973953 | 0.80 | ADORA2A (0.42) | ADORA2AADORA1ALDH1A1LMNA | |
| SCHEMBL147375 | 0.77 | ADORA2A (0.38) | ADORA2ACTSSMAPT | |
| SCHEMBL146763 | 0.73 | ADORA2A (0.36) | ADORA2AADORA1CTSSMAPTLMNA | |
| SCHEMBL147507 | 0.73 | ALDH1A1 (0.37) | MAPTALDH1A1 | |
| SCHEMBL10160856 | 0.71 | KMT2A (0.40) | ADORA2ACTSSMAPTALDH1A1 | |
| SCHEMBL147528 | 0.70 | MEN1 (0.33) | ACACA | |
| SCHEMBL10130820 | 0.70 | IDH1 (0.40) | ADORA2ACTSSALDH1A1 | |
| SCHEMBL22782191 | 0.65 | ADORA2A (0.33) | ADORA2ACTSS | |
| SCHEMBL148120 | 0.65 | SLC5A2 (0.36) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058941-A1 | GLUCOPYRANOSIDE COMPOUND | UGGT1, B3GAT3, FUT6 | ADORA2A 1452/4885ADORA1 1209/4885ACACA 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.